Table 1.
Characteristics of patients and univariate analysis of risk factors for 30-day mortality
| Variable | Total N = 84 |
30-day mortality Yes, N = 29 |
No, N = 55 | P value |
|---|---|---|---|---|
| Demographics | ||||
| Male gender | 52 (61.9) | 19 (65.5) | 33 (60.0) | 0.65 |
| Age (years) | 60.0 ± 21.1 | 64.5 ± 15.0 | 57.9 ± 14.9 | 0.06 |
| Weight (kg) | 67.7 ± 17.8 | 69.0 ± 14.0 | 70.5 ± 13.3 | 0.63 |
| Comorbidities | ||||
| Cardiovascular disease | 44 (52.4) | 21 (72.4) | 23 (41.8) | 0.01 |
| Chronic renal disease | 17 (20.2) | 10 (34.5) | 7 (12.7) | 0.02 |
| Baseline estimated GFR | 57.5 (28.5–106.5) | 59.0 (27–99) | 56.0 (32–128) | 0.75 |
| CNS | 17 (20.2) | 7 (24.1) | 10 (18.2) | 0.57 |
| Diabetes | 28 (33.3) | 11 (37.9) | 17 (30.9) | 0.63 |
| Digestive tract | 24 (28.6) | 7 (24.1) | 17 (20.9) | 0.62 |
| Chronic liver disease | 8 (9.5) | 3 (10.3) | 5 (9.1) | 1.00 |
| HIV | 2 (2.4) | 1 (3.4) | 1 (1.8) | 1.00 |
| Cancer | 27 (32.1) | 8 (27.6) | 19 (34.5) | 0.63 |
| Pulmonary disease | 25 (29.8) | 11 (37.9) | 14 (25.5) | 0.32 |
| Charlson | 4 (3–5) | 4 (3–6) | 4 (2–5) | 0.19 |
| Disease severity | ||||
| ICU admission | 37 (44.0) | 17 (58.6) | 20 (36.4) | 0.07 |
| Vasoactive drug | 25 (29.8) | 14 (48.3) | 11 (13.1) | 0.01 |
| Infection site | ||||
| Pulmonary | 23 (27.4) | 9 (31.0) | 14 (25.5) | 0.61 |
| Abdominal | 14 (16.7) | 2 (6.9) | 12 (21.8) | 0.12 |
| Upper urinary tract | 25 (29.8) | 8 (27.6) | 17 (30.9) | 0.80 |
| Skin and soft tissue | 4 (4.8) | 1 (3.4) | 3 (5.5) | 1.00 |
| Blood | 18 (21.4) | 9 (31.0) | 9 (16.4) | 0.16 |
| Bacterial isolates | ||||
| Time from admission to bacterial isolation | 28.1 (± 19.8) | 22.2 (± 23.3) | 16.4 (± 16.0) | 0.19 |
| Polymicrobial Infections | 25 (29.8) | 8 (27.6) | 17 (30.9) | 0.81 |
| Polymyxin resistance | 10 (11.6) | 4 (13.8) | 6 (10.5) | 0.73 |
| Amikacin MIC | 0.5 (0.5–1) | 1 (0.5–2) | 1 (0.5–2) | 0.24 |
| Therapy | ||||
| Amikacin dose (mg/kg/dia) | 13.1 ± 6.5 | 13.6 ± 6.1 | 13.3 ± 5.1 | 0.83 |
| Adequate dose adjustment for eGFR | 45 (53.2) | 15 (51.7) | 30 (54.5) | 0.82 |
| Time from bacterial isolation to start susceptible therapy (days) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.72 |
| Susceptible combination therapy | 58 (69.0) | 23(79.3) | 35 (63.6) | 0.21 |
| Antibiotic combination | ||||
| Polymyxin | 66 (78.6) | 27 (93.1) | 39 (70.9) | 0.02 |
| Polymixin B | 41 (48.8) | 17 (58.6) | 24 (43.6) | 0.25 |
| Colistin | 37 (44.0) | 14 (48.3) | 23 (41.8) | 0.64 |
| Meropenem | 48 (57.1) | 17 (58.6) | 31 (56.4) | 0.99 |
| Tigecycline | 2 (2.4) | 1 (3.4) | 1 (1.8) | 0.99 |
| Total time of amikacin therapy (days) | 12 (8–17.0) | 7 (2–10) | 10 (6–14) | 0.05 |
| Development of AKI | 29 (34.5) | 10 (34.5) | 19 (34.5) | 0.99 |
| Risk | 13 (15.5) | 4(13.8) | 9 (16.4) | |
| Injury | 11 (13.1) | 5 (17.2) | 6 (10.9) | |
| Failure | 5 (5.8) | 1 (3.4) | 4 (7.3) | |
Results are presented as: mean ± standard deviation, median (interquartile range) or absolute value (percentage); CNS, central nervous system; HIV, human immunodeficiency virus; MIC, minimal inhibitory concentration; eGFR, estimated glomerular filtration rate